中文English
ISSN 1001-5256
CN 22-1108/R

留言板

尊敬的读者、作者、审稿人, 关于本刊的投稿、审稿、编辑和出版的任何问题, 您可以本页添加留言。我们将尽快给您答复。谢谢您的支持!

姓名
邮箱
手机号码
标题
留言内容
验证码

药物性肝损伤的流行病学

李晓芸 唐洁婷

李晓芸,唐洁婷. 药物性肝损伤的流行病学[J]. 临床肝胆病杂志, 2021, 37(11): 2510-2514. DOI: 10.3969/j.issn.1001-5256.2021.11.002
引用本文: 李晓芸,唐洁婷. 药物性肝损伤的流行病学[J]. 临床肝胆病杂志, 2021, 37(11): 2510-2514. DOI: 10.3969/j.issn.1001-5256.2021.11.002
LI XY, TANG JT. Epidemiology of drug-induced liver injury [J]. J Clin Hepatol, 2021, 37(11): 2510-2514. DOI: 10.3969/j.issn.1001-5256.2021.11.002
Citation: LI XY, TANG JT. Epidemiology of drug-induced liver injury [J]. J Clin Hepatol, 2021, 37(11): 2510-2514. DOI: 10.3969/j.issn.1001-5256.2021.11.002

药物性肝损伤的流行病学

DOI: 10.3969/j.issn.1001-5256.2021.11.002
基金项目: 

上海交通大学医学院附属仁济医院临床科研创新培育基金 PYI20-05

详细信息
    通讯作者:

    唐洁婷,start_tjt@msn.com

  • 中图分类号: R575

Epidemiology of drug-induced liver injury

Research funding: 

Clinical Research Innovation Cultivation Fund of Renji hospital, Shanghai Jiao Tong University School of Medicine PYI20-05

  • 摘要: 药物性肝损伤(DILI)的发病率逐年上升,目前已成为临床常见的肝病之一, 受到全世界范围的广泛关注。已知多种药物,包括中草药和膳食补充剂均可导致各种类型的急慢性肝损伤,重者可出现急性肝衰竭,导致死亡或接受肝移植。就DILI的全球流行情况及常见可疑药物的分布进行了阐述。

     

  • 表  1  全球DILI流行病学现状

    研究 研究类型 持续年份 年发
    病率
    DILI总数
    (例)
    女性
    (%)
    主要年龄分布(岁) 慢性患者(%) 肝细胞型/
    胆汁淤积型/
    混合型(%)
    病死率
    (%)
    主要诱发DILI药物(%)
    冰岛 前瞻性 2010年—2011年 19.1/10万 96 56.25 40~59 7 42/32/26 1.04 抗菌药物(37.0)、HDS (16.0)、非甾体抗炎药(6.0)
    法国 前瞻性 1997年—2000年 13.9/10万 34 64.7 ≥50 47.1/20.6/26.5 5.88 抗感染药物(25.0)、精神药物(22.5)、降血脂药物(12.5)和非甾体抗炎药(10.0)
    美国 前瞻性 2004年—2013年 2.7/10万
    成年人,
    特拉华州
    899 59 18 54/23/23 6 抗菌药物(45.4)、HDS(16.1)、心血管系统药物(9.8)、中枢神经系统药物(9.1)
    西班牙 前瞻性 1994年—2004年 3.42/10万 461 48.65 ≥60 10.31 57.8/20.0/22.2 5.38 阿莫西林-克拉维酸(13.23)、结核病药物(6.95)、依溴替丁(4.93)
    瑞典 回顾性 1970年—2004年 2.4/10万 784 57.7 52.2/26.3/21.5 9.18 抗生素(27.04)、非甾体抗炎药(4.85)、麻醉药(1.91)
    印度 回顾性 1997年—2008年 313 42 0.32 17.3 结核病药物(57.8)、苯妥英钠(6.7)、奥氮平(5.4)、氨苯砜(5.4)
    日本 回顾性 1997年—2006年 1676 57 50~69 59/20/21 0.4 抗生素(14.3)、精神药物和神经系统药物(10.1)、HDS(10.0)
    中国 回顾性 2012年—2014年 23.80/10万 25 927 49.17 40~59 13 51.39/20.31/28.30 0.39 传统中药或HDS(26.81)、抗结核药物(21.99)、抗肿瘤药物或免疫调节剂(8.34)、抗感染药物(6.08)
    下载: 导出CSV
  • [1] CHALASANI NP, HAYASHI PH, BONKOVSKY HL, et al. ACG Clinical Guideline: The diagnosis and management of idiosyncratic drug-induced liver injury[J]. Am J Gastroenterol, 2014, 109(7): 950-966; quiz 967. DOI: 10.1038/ajg.2014.131.
    [2] ANDRADE RJ, CHALASANI N, BJÖRNSSON ES, et al. Drug-induced liver injury[J]. Nat Rev Dis Primers, 2019, 5(1): 58. DOI: 10.1038/s41572-019-0105-0.
    [3] Drug-induced Liver Disease Study Group, Chinese Society of Hepatology, Chinese Medical Association. Guidelines for the management of drug-induced liver injury[J]. J Clin Hepatol, 2015, 31(11): 1752-1769. DOI: 10.3969/j.issn.1001-5256.2015.11.002.

    中华医学会肝病学分会药物性肝病学组. 药物性肝损伤诊治指南[J]. 临床肝胆病杂志, 2015, 31(11): 1752-1769. DOI: 10.3969/j.issn.1001-5256.2015.11.002.
    [4] BJÖRNSSON ES, BERGMANN OM, BJÖRNSSON HK, et al. Incidence, presentation, and outcomes in patients with drug-induced liver injury in the general population of Iceland[J]. Gastroenterology, 2013, 144(7): 1419-1425, 1425. e1-3; quiz e19-20. DOI: 10.1053/j.gastro.2013.02.006.
    [5] SGRO C, CLINARD F, OUAZIR K, et al. Incidence of drug-induced hepatic injuries: A French population-based study[J]. Hepatology, 2002, 36(2): 451-455. DOI: 10.1053/jhep.2002.34857.
    [6] JICK H, DERBY LE, GARCíA RODRÍGUEZ LA, et al. Liver disease associated with diclofenac, naproxen, and piroxicam[J]. Pharmacotherapy, 1992, 12(3): 207-212.
    [7] DERBY LE, JICK H, HENRY DA, et al. Cholestatic hepatitis associated with flucloxacillin[J]. Med J Aust, 1993, 158(9): 596-600. DOI: 10.5694/j.1326-5377.1993.tb137624.x.
    [8] DERBY LE, JICK H, HENRY DA, et al. Erythromycin-associated cholestatic hepatitis[J]. Med J Aust, 1993, 158(9): 600-602. DOI: 10.5694/j.1326-5377.1993.tb137625.x.
    [9] GARCÍA RODRÍGUEZ LA, STRICKER BH, ZIMMERMAN HJ. Risk of acute liver injury associated with the combination of amoxicillin and clavulanic acid[J]. Arch Intern Med, 1996, 156(12): 1327-1332. DOI: 10.1001/archinte.1996.00440110099013.
    [10] GARCÍA RODRÍGUEZ LA, WALLANDER MA, STRICKER BH. The risk of acute liver injury associated with cimetidine and other acid-suppressing anti-ulcer drugs[J]. Br J Clin Pharmacol, 1997, 43(2): 183-188. DOI: 10.1046/j.1365-2125.1997.05268.x.
    [11] JICK H, DERBY LE. A large population-based follow-up study of trimethoprim-sulfamethoxazole, trimethoprim, and cephalexin for uncommon serious drug toxicity[J]. Pharmacotherapy, 1995, 15(4): 428-432.
    [12] DERBY LE, GUTTHANN SP, JICK H, et al. Liver disorders in patients receiving chlorpromazine or isoniazid[J]. Pharmacotherapy, 1993, 13(4): 353-358.
    [13] GARCÍA RODRÍGUEZ LA, WILLIAMS R, DERBY LE, et al. Acute liver injury associated with nonsteroidal anti-inflammatory drugs and the role of risk factors[J]. Arch Intern Med, 1994, 154(3): 311-316. DOI: 10.1001/archinte.1994.00420030117012.
    [14] de ABAJO FJ, MONTERO D, MADURGA M, et al. Acute and clinically relevant drug-induced liver injury: A population based case-control study[J]. Br J Clin Pharmacol, 2004, 58(1): 71-80. DOI: 10.1111/j.1365-2125.2004.02133.x.
    [15] VEGA M, VERMA M, BESWICK D, et al. The incidence of drug- and herbal and dietary supplement-induced liver injury: Preliminary findings from gastroenterologist-based surveillance in the population of the state of delaware[J]. Drug Saf, 2017, 40(9): 783-787. DOI: 10.1007/s40264-017-0547-9.
    [16] AISO M, TAKIKAWA H, TSUJI K, et al. Analysis of 307 cases with drug-induced liver injury between 2010 and 2018 in Japan[J]. Hepatol Res, 2019, 49(1): 105-110. DOI: 10.1111/hepr.13288.
    [17] BAGHERI H, MICHEL F, LAPEYRE-MESTRE M, et al. Detection and incidence of drug-induced liver injuries in hospital: A prospective analysis from laboratory signals[J]. Br J Clin Pharmacol, 2000, 50(5): 479-484. DOI: 10.1046/j.1365-2125.2000.00282.x.
    [18] MEIER Y, CAVALLARO M, ROOS M, et al. Incidence of drug-induced liver injury in medical inpatients[J]. Eur J Clin Pharmacol, 2005, 61(2): 135-143. DOI: 10.1007/s00228-004-0888-z.
    [19] CANO-PANIAGUA A, AMARILES P, ANGULO N, et al. Epidemiology of drug-induced liver injury in a University Hospital from Colombia: Updated RUCAM being used for prospective causality assessment[J]. Ann Hepatol, 2019, 18(3): 501-507. DOI: 10.1016/j.aohep.2018.11.008.
    [20] SUK KT, KIM DJ, KIM CH, et al. A prospective nationwide study of drug-induced liver injury in Korea[J]. Am J Gastroenterol, 2012, 107(9): 1380-1387. DOI: 10.1038/ajg.2012.138.
    [21] SHEN T, LIU Y, SHANG J, et al. Incidence and etiology of drug-induced liver injury in mainland China[J]. Gastroenterology, 2019, 156(8): 2230-2241. e11. DOI: 10.1053/j.gastro.2019.02.002.
    [22] de VALLE MB, AV KLINTEBERG V, ALEM N, et al. Drug-induced liver injury in a Swedish University hospital out-patient hepatology clinic[J]. Aliment Pharmacol Ther, 2006, 24(8): 1187-1195. DOI: 10.1111/j.1365-2036.2006.03117.x.
    [23] BJÖRNSSON E, ISMAEL S, NEJDET S, et al. Severe jaundice in Sweden in the new millennium: Causes, investigations, treatment and prognosis[J]. Scand J Gastroenterol, 2003, 38(1): 86-94. DOI: 10.1080/00365520310000492.
    [24] VUPPALANCHI R, LIANGPUNSAKUL S, CHALASANI N. Etiology of new-onset jaundice: How often is it caused by idiosyncratic drug-induced liver injury in the United States?[J]. Am J Gastroenterol, 2007, 102(3): 558-562; quiz 693. DOI: 10.1111/j.1572-0241.2006.01019.x.
    [25] WEI G, BERGQUIST A, BROOMÉ U, et al. Acute liver failure in Sweden: Etiology and outcome[J]. J Intern Med, 2007, 262(3): 393-401. DOI: 10.1111/j.1365-2796.2007.01818.x.
    [26] OSTAPOWICZ G, FONTANA RJ, SCHIØDT FV, et al. Results of a prospective study of acute liver failure at 17 tertiary care centers in the United States[J]. Ann Intern Med, 2002, 137(12): 947-954. DOI: 10.7326/0003-4819-137-12-200212170-00007.
    [27] REUBEN A, KOCH DG, LEE WM. Drug-induced acute liver failure: Results of a U.S. multicenter, prospective study[J]. Hepatology, 2010, 52(6): 2065-2076. DOI: 10.1002/hep.23937.
    [28] GOLDBERG DS, FORDE KA, CARBONARI DM, et al. Population-representative incidence of drug-induced acute liver failure based on an analysis of an integrated health care system[J]. Gastroenterology, 2015, 148(7): 1353-1361. e3. DOI: 10.1053/j.gastro.2015.02.050.
    [29] GARCÍA RODRÍGUEZ LA, RUIGÓMEZ A, JICK H. A review of epidemiologic research on drug-induced acute liver injury using the general practice research data base in the United Kingdom[J]. Pharmacotherapy, 1997, 17(4): 721-728.
    [30] CHALASANI N, BONKOVSKY HL, FONTANA R, et al. Features and outcomes of 899 patients with drug-induced liver injury: The DILIN prospective study[J]. Gastroenterology, 2015, 148(7): 1340-1352. e7. DOI: 10.1053/j.gastro.2015.03.006.
    [31] DEVARBHAVI H, DIERKHISING R, KREMERS WK, et al. Single-center experience with drug-induced liver injury from India: Causes, outcome, prognosis, and predictors of mortality[J]. Am J Gastroenterol, 2010, 105(11): 2396-2404. DOI: 10.1038/ajg.2010.287.
    [32] NAVARRO VJ, BARNHART H, BONKOVSKY HL, et al. Liver injury from herbals and dietary supplements in the U.S. Drug-Induced Liver Injury Network[J]. Hepatology, 2014, 60(4): 1399-1408. DOI: 10.1002/hep.27317.
    [33] TESCHKE R, EICKHOFF A. Herbal hepatotoxicity in traditional and modern medicine: Actual key issues and new encouraging steps[J]. Front Pharmacol, 2015, 6: 72. DOI: 10.3389/fphar.2015.00072.
    [34] HELMY A. Review article: Updates in the pathogenesis and therapy of hepatic sinusoidal obstruction syndrome[J]. Aliment Pharmacol Ther, 2006, 23(1): 11-25. DOI: 10.1111/j.1365-2036.2006.02742.x.
    [35] European Association for the Study of the Liver. EASL Clinical Practice Guidelines: Drug-induced liver injury[J]. J Hepatol, 2019, 70(6): 1222-1261. DOI: 10.1016/j.jhep.2019.02.014.
    [36] LUCENA MI, ANDRADE RJ, FERNÁNDEZ MC, et al. Determinants of the clinical expression of amoxicillin-clavulanate hepatotoxicity: A prospective series from Spain[J]. Hepatology, 2006, 44(4): 850-856. DOI: 10.1002/hep.21324.
    [37] LUCENA MI, ANDRADE RJ, KAPLOWITZ N, et al. Phenotypic characterization of idiosyncratic drug-induced liver injury: The influence of age and sex[J]. Hepatology, 2009, 49(6): 2001-2009. DOI: 10.1002/hep.22895.
    [38] MOLLESTON JP, FONTANA RJ, LOPEZ MJ, et al. Characteristics of idiosyncratic drug-induced liver injury in children: Results from the DILIN prospective study[J]. J Pediatr Gastroenterol Nutr, 2011, 53(2): 182-189. DOI: 10.1097/MPG.0b013e31821d6cfd.
    [39] CHALASANI N, FONTANA RJ, BONKOVSKY HL, et al. Causes, clinical features, and outcomes from a prospective study of drug-induced liver injury in the United States[J]. Gastroenterology, 2008, 135(6): 1924-1934, 1934. e1-4. DOI: 10.1053/j.gastro.2008.09.011.
    [40] LARREY D. Epidemiology and individual susceptibility to adverse drug reactions affecting the liver[J]. Semin Liver Dis, 2002, 22(2): 145-155. DOI: 10.1055/s-2002-30105.
    [41] ANDRADE RJ, LUCENA MI, FERNÁNDEZ MC, et al. Drug-induced liver injury: An analysis of 461 incidences submitted to the Spanish registry over a 10-year period[J]. Gastroenterology, 2005, 129(2): 512-521. DOI: 10.1016/j.gastro.2005.05.006.
    [42] ORTEGA-ALONSO A, STEPHENS C, LUCENA MI, et al. Case characterization, clinical features and risk factors in drug-induced liver injury[J]. Int J Mol Sci, 2016, 17(5). DOI: 10.3390/ijms17050714.
    [43] DEVARBHAVI H. An update on drug-induced liver injury[J]. J Clin Exp Hepatol, 2012, 2(3): 247-259. DOI: 10.1016/j.jceh.2012.05.002.
  • 加载中
表(1)
计量
  • 文章访问数:  173
  • HTML全文浏览量:  34
  • PDF下载量:  130
  • 被引次数: 0
出版历程
  • 收稿日期:  2021-08-31
  • 录用日期:  2021-08-31
  • 出版日期:  2021-11-20
  • 分享
  • 用微信扫码二维码

    分享至好友和朋友圈

目录

    /

    返回文章
    返回